Developing World Bioethics · 2003 · 37 citations · 0 references
LawIntellectual Property LawPharmaceutical PolicyIntellectual PropertyPatent LawPharmaceutical RegulationAccess To MedicinesIntellectual Property PolicyIntellectual Property ProtectionIntellectual Property RightsInternational Intellectual Property LawPharmaceutical GovernanceInternational Pharmaceutical Trade AgreementsMedicines Pricing PolicyPharmaceutical AccessPharmaceutical Innovation IncentivesPharmaceutical Patent PolicyPharmaceutical Policy EvaluationUtilitarian ReasoningWorld Bank Group
In this paper, we provide an overview of how the outcomes of the Uruguay Round affected the application of pharmaceutical intellectual property rights globally. Second, we explain how specific pharmaceutical policy tools can help developing states mitigate the worst effects of the TRIPS Agreement. Third, we put forward solutions that could be implemented by the World Bank to help overcome the divide between creating private incentives for research and development of innovative medicines and ensuring access of the poor to medicine. Fourth, we evaluate these solutions on the basis of utilitarian considerations and urge that equitable pricing is morally preferable to the other solutions.